Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for $305 million. Wojcicki’s return is likely to spark lawsuits. The nonprofit,

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a non-profit led by the company’s co-founder and former CEO Anne Wojcicki proposed a better offer to acquire the bankrupt DNA testing company.